Meenalshi kanwar chauhan
@sru.edu.in
Professor of Pharmaceutics
Govt of NCT of Delhi DPSRU New Delhi
RESEARCH INTERESTS
Pharmaceutics
Pharmaceutical Technology
Nano technology
Transdermal
Ophthalmic Drug Delivery
Protein Peptide Drug delivery
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Nidhi Gupta, Pankaj Kumar Sharma, Shreyash Santosh Yadav, Meenakshi Chauhan, Ashok Kumar Datusalia, and Sampa Saha
American Chemical Society (ACS)
Parkinson's is a progressive neurodegenerative disease of the nervous system. It has no cure, but its symptoms can be managed by supplying dopamine artificially to the brain.This work aims to engineer tricompartmental polymeric microcarriers by electrohydrodynamic cojetting technique to encapsulate three PD (Parkinson's disease) drugs incorporated with high encapsulation efficiency (∼100%) in a single carrier at a fixed drug ratio of 4:1:8 (Levodopa (LD): Carbidopa(CD): Entacapone (ENT)). Upon oral administration, the drug ratio needs to be maintained during subsequent release from microparticles to enhance the bioavailability of primary drug LD. This presents a notable challenge, as the three drugs vary in their aqueous solubility (LD > CD > ENT). The equilibrium of therapeutic release was achieved using a combination of FDA-approved polymers (PLA, PLGA, PCL, and PEG) and the disc shape of particles. In vitro studies demonstrated the simultaneous release of all the three therapeutics in a sustained and controlled manner. Additionally, pharmacodynamics and pharmacokinetics studies in Parkinson's disease rats induced by rotenone showed a remarkable improvement in PD conditions for the microparticles-fed rats, thereby showing a great promise toward efficient management of PD.
Uzma Hasan, Meenakshi Chauhan, Suparna Mercy Basu, Jayakumar R., and Jyotsnendu Giri
Springer Science and Business Media LLC
Anil Sao, Tulsidas Nimbekar, Garla Venkateswarlu, Mohit Mishra, Aditya Kate, Meenakshi Kanwar Chauhan, and Chandrashekhar Mahadeo Chakole
Bentham Science Publishers Ltd.
Background: The entire world witnessed the COVID-19 pandemic outbreak. It has become deadly everywhere across the globe. COVID-19 mortality varies across age groups and has been linked to an individual's innate immunity. In contrast, it was more lethal in immunocompromised people. The spread of viruses is slowed by both passive immunity and vaccine-aided acquired immunity. However, vaccine-induced immunity is transient, and there is no assurance that vaccinemediated antibodies will be effective against all future virus mutants. As a result, natural immunity boosters have become essential supplements that must be used nowadays to stay immunized against such infections. In Ayurvedic medicine, traditional Indian spices have been used for a long time to boost the immune system and fight off different diseases. Objective: This review aims to disseminate information about traditional natural medicine in repurposing as an immunity booster and for antiviral effects in COVID-19. Methods: Using published articles from recent years, the in silico docking study, survey-based study, and in vitro and preclinical research work on selected traditional herbs for their anti-inflammatory, immunomodulating, and antiviral properties are summarized. Withania somnifera, Piper nigrum, Emblica officinalis, Andrographis paniculate, Glycyrrhiza glabra, Ocimum sanctum, Piper longum, and Curcuma longa are some of the most commonly used natural spices studied extensively and hence selected in this review. Results: This context summarizes selected plants showing immunomodulatory and antiviral effects in experimental animals, simulation, and clinical studies. Conclusion: By virtue of antiviral potential, the chosen herbs could be used for repurposing in COVID-19 management after thorough clinical investigations.
Alisha Sachdeva, Monika Targhotra, Meenakshi Kanwar Chauhan, and Monica Chopra
Bentham Science Publishers Ltd.
Background: Regardless of the most recent inclusion of mold-active agents (isavuconazole and posaconazole) to antifungal agents against mucormycosis, in conjunction with amphotericin B (AMB) items, numerous uncertainties still exist regarding the treatment of this rare infection. The order Mucorales contains a variety of fungi that cause the serious but uncommon fungal illness known as mucormycosis. The moulds are prevalent in nature and typically do not pose significant risks to people. Immunocompromised people are affected by it. Objective: This article's primary goal is to highlight the integral role that AMB plays in this condition. Methods: Like sinusitis (including pansinusitis, rhino-orbital, or rhino-cerebral sinusitis) is one of the many signs and symptoms of mucormycosis. The National Center for Biotechnology Information (NCBI) produces a variety of online information resources for review articles on the topic-based mucormycosis, AMB, diagnosis of mucormycosis and the PubMed® database of citations and abstracts published in life science journals. These resources can be accessed through the NCBI home page at https://www.ncbi.nlm.nih.gov. Results: The article provides a summary of the pharmacological attributes of the various AMB compositions accessible for systemic use. Conclusion: The article demonstrates the traits of the drug associated with its chemical, pharmacokinetics, stability, and other features, and illustrates their most useful characteristics for clinical application.
Suparna Mercy Basu, Meenakshi Chauhan, and Jyotsnendu Giri
American Chemical Society (ACS)
Cancer stem cells (CSCs) present a formidable challenge in cancer treatment due to their inherent resistance to chemotherapy, primarily driven by the overexpression of ABC transporters and multidrug resistance (MDR). Despite extensive research on pharmacological small-molecule inhibitors, effectively managing MDR and improving chemotherapeutic outcomes remain elusive. On the other hand, magnetic hyperthermia (MHT) holds great promise as a cancer therapeutic, but there is limited research on its potential to reverse MDR in breast CSCs and effectively eliminate CSCs through combined chemo-hyperthermia. To address these gaps, we developed tumor microenvironment-sensitive, drug-loaded poly(propylene sulfide) (PPS)-coated magnetic nanoparticles (PPS-MnFe). These nanoparticles were employed to investigate hyperthermia sensitivity and MDR reversion in breast CSCs, comparing their performance to that of small-molecule inhibitors. Additionally, we explored the efficacy of combined chemo-hyperthermia in killing CSCs. CSC-enriched breast cancer cells were subjected to low-dose MHT at 42 °C for 30 min and then treated with the chemical MDR inhibitor salinomycin (SAL). The effectiveness of each treatment in inhibiting MDR was assessed by measuring the efflux of the MDR substrate, rhodamine 123 (R123) dye. Notably, MHT induced a prolonged reversal of MDR activity compared with SAL treatment alone. After successfully inhibiting MDR, the breast CSCs were exposed to chemotherapy using paclitaxel to trigger synergistic cell death. The combination of MHT and chemotherapy demonstrated remarkable reductions in stemness properties, MDR reversal, and the effective eradication of breast CSCs in this innovative dual-modality approach.
D. Keerthana, Devendra Mishra, Meenakshi Kanwar Chauhan, and Monica Juneja
Springer Science and Business Media LLC
Mohd. Aqil, Mamta Bishnoi, and Meenakshi Kanwar Chauhan
Springer Science and Business Media LLC
Nimeet Desai, Uzma Hasan, Jeyashree K, Rajesh Mani, Meenakshi Chauhan, Suparna Mercy Basu, and Jyotsnendu Giri
Elsevier BV
Aditya Kate, Ekkita Seth, Ananya Singh, Chandrashekhar Mahadeo Chakole, Meenakshi Kanwar Chauhan, Ravi Kant Singh, Shrirang Maddalwar, and Mohit Mishra
Georg Thieme Verlag KG
AbstractThe continuous implementation of Artificial Intelligence (AI) in multiple scientific domains and the rapid advancement in computer software and hardware, along with other parameters, have rapidly fuelled this development. The technology can contribute effectively in solving many challenges and constraints in the traditional development of the drug. Traditionally, large-scale chemical libraries are screened to find one promising medicine. In recent years, more reasonable structure-based drug design approaches have avoided the first screening phases while still requiring chemists to design, synthesize, and test a wide range of compounds to produce possible novel medications. The process of turning a promising chemical into a medicinal candidate can be expensive and time-consuming. Additionally, a new medication candidate may still fail in clinical trials even after demonstrating promise in laboratory research. In fact, less than 10% of medication candidates that undergo Phase I trials really reach the market. As a consequence, the unmatched data processing power of AI systems may expedite and enhance the drug development process in four different ways: by opening up links to novel biological systems, superior or distinctive chemistry, greater success rates, and faster and less expensive innovation trials. Since these technologies may be used to address a variety of discovery scenarios and biological targets, it is essential to comprehend and distinguish between use cases. As a result, we have emphasized how AI may be used in a variety of areas of the pharmaceutical sciences, including in-depth opportunities for drug research and development.
Nitin Yadav, Utkarsh Kumar, Purandhi Roopmani, Uma Maheswari Krishnan, Swaminathan Sethuraman, Meenakshi K. Chauhan, and Virander S. Chauhan
American Chemical Society (ACS)
Himanshu Kushwah, Nidhi Sandal, Meenakshi Chauhan, and Gaurav Mittal
SAGE Publications
Management of uncontrolled bleeding due to traumatic injuries occurring in battlefields and road traffic accidents is a major healthcare concern, especially in developing countries like India. Since natural coagulation mechanism alone is insufficient to achieve haemostasis quickly in such cases, application of an external haemostatic product is generally required to accelerate the coagulation process. We had recently reported preliminary comparison of four natural absorbent gums, which indicated towards haemostatic potential of gum tragacanth (GT) and xanthan gum (XG). Present study involves fabrication of haemostatic dressings incorporated with different concentrations of GT or XG, along with ciprofloxacin (a broad-spectrum antibiotic) and other excipients over woven cotton gauze. Prepared gauzes were investigated for physico-chemical characteristics, in-vitro blood interaction studies, antibacterial effect and in-vivo haemostatic efficacy in Sprague Dawley rats using two bleeding models. Acute dermal toxicity studies were also carried out as per OECD guidelines. SEM studies showed that gauzes coated with XG had thin, uniform layer of coating, while in case of GT; coating was comparatively rough with insoluble particles of GT adhering over gauze surface, forming voids on the fibers. Coated gauzes exhibited optimum mechanical properties in terms of tensile strength and percent extension at break. GT coated dressings showed good fluid uptake and retention ability in-vitro. Test gauzes were non-hemolytic in nature, did not elicit any dermal toxicity on animals’ skin and had the ability to protect against E. coli infection. In-vivo efficacy studies in rat femoral artery and liver laceration bleeding models indicated that gauzes coated with 4% GT were able to clot blood in least time (36.67 ± 3.33s and 40 ± 2.58s respectively) as compared to other gum combinations and commercially available dressing ‘Surgispon® (103.3 ± 4.22s and 85 ± 5.62s respectively). Results of this study validate our initial findings of the potential of gum tragacanth to be developed into a suitable haemostatic product.
Meenakshi Chauhan, Suparna Mercy Basu, Mohd Qasim, and Jyotsnendu Giri
Royal Society of Chemistry (RSC)
Magnetic nanoparticle delivery systems are promising for targeted drug delivery, imaging, and chemo-hyperthermia of cancer; but their toxicity from reactive oxygen species generation, targeted delivery, and biodegradation limits their use.
Monika Targhotra and Meenakshi Kanwar Chauhan
Elsevier
Nitin Yadav, Utkarsh Kumar, Purandhi Roopmani, Uma Maheswari Krishnan, Swaminathan Sethuraman, Meenakshi K. Chauhan, and Virander S. Chauhan
American Chemical Society (ACS)
The use of hydrogels as scaffolds for three-dimensional (3D) cell growth is an active area of research in tissue engineering. Herein, we report the self-assembly of an ultrashort peptide, a tetrapeptide, Asp-Leu-IIe-IIe, the shortest peptide sequence from a highly fibrillogenic protein TDP-43, into the hydrogel. The hydrogel was mechanically strong and highly stable, with storage modulus values in MPa ranges. The hydrogel supported the proliferation and successful differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) in its matrix as assessed by cell viability, calcium deposition, alkaline phosphatase (ALP) activity, and the expression of osteogenic marker gene studies. To check whether the hydrogel supports 3D growth and regeneration in in vivo conditions, a rabbit critical bone defect model was used. Micro-computed tomography (CT) and X-ray analysis demonstrated the formation of mineralized neobone in the defect areas, with significantly higher bone mineralization and relative bone densities in animals treated with the peptide hydrogel compared to nontreated and matrigel treatment groups. The ultrashort peptide-based hydrogel developed in this work holds great potential for its further development as tissue regeneration and/or engineering scaffolds.
Mahendra Yadav, Vivek Kumar, Nidhi Sandal, and Meenakshi Kanwar Chauhan
Springer Science and Business Media LLC
Nandini Sarviya, Suparna Mercy Basu, Rajesh Mani, Meenakshi Chauhan, Peter Kingshott, and Jyotsnendu Giri
Elsevier BV
Mahendra Yadav, Komal Rani, Nidhi Sandal, and Meenakshi Kanwar Chauhan
Springer Science and Business Media LLC
Mahendra Yadav, Vivek Kumar, Nidhi Sandal, and Meenakshi K. Chauhan
Springer Science and Business Media LLC
Shweta Mittal, Chandrashekhar Mahadeo Chakole, Aman Sharma, Jaya Pandey, and Meenakshi Kanwar Chauhan
Georg Thieme Verlag KG
AbstractNanotechnology-based nanomedicine offers several benefits over conventional forms of therapeutic agents. Moreover, nanomedicine has become a potential candidate for targeting therapeutic agents at specific sites. However, nanomedicine prepared by synthetic methods may produce unwanted toxic effects. Due to their nanosize range, nanoparticles can easily reach the reticuloendothelial system and may produce unwanted systemic effects. The nanoparticles produced by the green chemistry approach would enhance the safety profile by avoiding synthetic agents and solvents in its preparations. This review encompasses toxicity consideration of nanoparticles, green synthesis techniques of nanoparticle preparation, biomedical application of nanoparticles, and future prospects.
Meenakshi Chauhan, Suparna Mercy Basu, Sunil Kumar Yadava, Nandini Sarviya, and Jyotsnendu Giri
Wiley
Pankaj Kumar Sharma, Hanuman Prasad Sharma, Chandrashekhar Mahadeo Chakole, Jaya Pandey, and Meenakshi Kanwar Chauhan
Elsevier BV
Ruby Singh, Purandhi Roopmani, Meenakshi Chauhan, Suparna Mercy Basu, Waghela Deeksha, M.D. Kazem, Sarbani Hazra, Eerappa Rajakumara, and Jyotsnendu Giri
Elsevier BV
Chandrashekhar Mahadeo Chakole, P.K. Sahoo, Jaya Pandey, and Meenakshi Kanwar Chauhan
Elsevier BV
Mahendra Yadav, Pooja Sharma, Himanshu Kushwah, Nidhi Sandal, and Meenakshi Kanwar Chauhan
Springer Science and Business Media LLC